An interventional study of Muscle power assessment and Muscle force assessment in Knee Osteoarthritis (Knee OA) and Falls Prevention, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli — 13 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Knee · Istituto Ortopedico Rizzoli.
Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 21 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 30th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →13 of the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–60
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–65
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–85
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40–75
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 18–40
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 65 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 50 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 50 across the 25 interventional studies, 105 across the 6 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
4 of the studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06726629Istituto Ortopedico RizzoliCrosscultural Adaptation And Validation Of The Italian Version Of The New Knee Society Knee Scoring System | 2026-11 |
| NCT06251752Istituto Ortopedico RizzoliLong Term Evaluation of Clinical and Radiologic Results on Femoro-patellar Joint After High Tibial Osteotomy | 2026-12 |
| NCT06040957Istituto Ortopedico RizzoliBone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis | 2027-01 |
| NCT06490770Istituto Ortopedico RizzoliAnalysis of the Pathophysiological and Functional State of the Knee Joint | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The twofold goal of this study is to understand the link between muscle power, muscle strength, and muscle control degradation with the risk of falling, and to develop a framework for the comprehensive and quantitative assessment of muscle power (and strength) in an elderly population of patients with knee osteoarthritis, who are at higher risk of falling. The main question it aims to answer is:
● Are muscle power and motor control degradation better predictors of falls than muscle strength in the aging population?
Participants will undergo:
Falls are a critical yet common event among the elderly, with huge societal and economic impact (reduced quality of life and high costs for the healthcare system). Experimental measures to quantify the residual muscle strength and power may provide useful information to predict the risk of falls in the elderly. Isometric and isokinetic muscle contractions, performed on a dynamometer or during functional tasks can be collected, together with electromyography (to assess muscle activity) and imaging data (to quantify and characterize muscular tissue).
Such data can be collected at different time points to monitor subjects over time, and to inform virtual representation of the human musculoskeletal system (digital twins) to identify possible motor control deficits. Moreover, this same information can be used to better characterize/assess elder individuals at risk of falling (e.g., subjects with knee osteoarthritis), to prevent future falls.
All subjects enrolled in the PowerAGING study will be followed up for 24 months (5 visits in total: M0, M6, M12, M18 and M24 follow-up). At each visit, a series of experimental tests to quantify muscle power and muscle force, as well as a home-based mobility assessment (via single inertial sensor worn for 5 consecutive days), will be performed. In addition, only at start and end, the subjects will undergo a full lower limb MRI and a gait assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Elderly patients with knee osteoarthritis, without a history of falls (in the 12 months prior to enrollment). All subjects will be followed up for 24 months, every 6 months. Muscle force and power assessments, plus a home-based mobility monitoring, will be performed at all visits. Full lower limb MRI and a gait assessment will be performed at first and last visit.
Other: Muscle power assessment · Other: Muscle force assessment · Other: Home-based mobility monitoring · Diagnostic Test: Magnetic Resonance Imaging · Other: Gait assessment
Isokinetic dynamometry test Stair ascent/descent on instrumented stairs
Isometric dynamometry (Maximal Voluntary Isometric Contraction)
Mobility monitoring with wearable sensors
Full lower limb MRI
Motion capture, surface EMG and gorund reaction force data
Maximal muscle force
Maximal Isometric muscle force from dynamometry test
Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)
Muscle power
Assessed on the dynamometer and during dynamic tasks
Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)
Muscle activations
From surface EMG data collected on the dynamometer and during dynamic tasks (gait assessment and stair ascent/descent)
Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)
Digital Mobility Outcomes
Qualitative and quantiative measures of real-world mobility (e.g., gait speed, stride length)
Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)
Musculoskeletal model predictions
Estimates of muscle force and knee joint contact forces
Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)
Muscle volumes
Estimation of muscle volumes (cm3)
Time frame: From first follow-up visit (Month 6) to last follow-up visit (Month 24)
Started Jan 2025 (actual). Primary completion is estimated for Dec 2028, 47 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 47 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Dec 2028 and completion Dec 2026 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.